Icon
+91 94997 68112
Login Register

ProAir HFA - (EQ 0.09MG BASE/INH; Aerosol, Metered: Inhalation)

Albuterol Sulphate Teva
EQ 0.09MG BASE/INH; Aerosol, Metered: Inhalation
More Than $1000 mn
Less Than 5
Less Than 5
More Than 5
 None
Less Than 5
Less Than 5
Indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Yes
******* ** *** ****** *** **** ***-*** ***. ********** ** ******* **** ******* ***** ********* ** *** ***** ** ********** ******* *** * ******* ******** ******* ** ****** * ******* ******* ** ******® *** ******** ** ******** **, **** (** ******* ** ******* *************) *** ** ********* ******** ******* ********* ***** **** **, ****. ******* *** *** ******** ********* ******** ***. ********* ** ****'* *** **** **-*, **** **** *** ********* ******* *********** ** ***** ******* ** ****. ********* ** ****** *******, ** ** **** ********* **** *******. ***** ***** **** ** ****** ** ** ******* ********* (*** **, ****), ********* (*** *, ****) *** ********* (*** **, ****) *** *** ************ **** ** ****. ****** *** ****** ** ** ****** ****, ********** *** ********* **** ***** ** **** ***** *** ***** ** ********* *** *** ***** *** ** ****** ***** ** ****** * ****** ***** *******.
ProAir HFA Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10
******* ******* ******* ******* ******* ******* ******* ******* *** ********* (***** ****** *******) *** ********* (***** ****** *******) *** ********* (***** ****** *******)
***** ******* ******* ******* ******* ******* ******* ******* *** ********* (***** ****** *******) *** ********* (***** ****** *******) *** ********* (***** ****** *******)
****** *** ********* *** ********* *** ********* *** ********* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** ****** ******** **** ** *** **, ****
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** ***** *, **** ******* ******** ************ ******** ** *** **, ****
***** ** \ ** **** **, **** ******* ******** ******** ** *** **, ****
****** ** \ ** *** **, **** ******* **** *** ****** *** ****
  1. **** **, **** : ******* ******** **** ***** *** **** ** *** ***-*** *** *********** ******* '***-**** **, **** *** '***-**** *, ****.
  2. **** *, **** : **** ********* ******* ** ******** ** ********.
  3. *** **, **** : ********** *** ********* **** ******* ***** ********* ** *** ***** ** ********** ***** *** * ******* ******** ******* ** ****** * ******* ******* ** ******® *** ******** ** ******** **, **** (** ******* ** ******* *************) *** ** ********* ******** ******* ********* ***** **** **, ****..
  4. *** *, **** : ***** ******** **** ********* **** ** ****** ** ** ******* ********* (*** **, ****), ********* (*** *, ****) *** ********* (*** **, ****).
  5. *** **, **** : **** **** ***** ** ** ** ********.
  6. *** *, **** : **** ******* ***** ** *********.
  7. *** **, **** : ****** ******** **** ********* **** ** ******.
  8. *** *, **** : **** **** ****** **** ************ ** ’***, ’***, ’***, ’***, ’***, *** ’*** ******.
  9. *** **, **** : **** ***** *** ******* ********* ******* ****** **** ******* ************ ** ’***, ’***, ’***, ’***, *** ’*** ******.
  10. *** **, **** : **** ******** ******** **** ***** *** **** ** ******.
  11. *** **, **** : **** **** **** ******** **** ************ ** ****** ** '***, '***, '***, '***, '***, '***, '***, '*** *** '***.
  12. *** **, **** : ********* ****** (********* ******) *** ***** ******** *** ** ******** ** ****** *** ******* ** *** ******* ** ****.
  13. *** **, **** : ********* ** **'* *******, ****** ** '***, '***, '***, '*** *** '*** *** *** ******** ****** ** ****** **** ** ****** ** **** *******. **** **** ******* ** ****** *** ******** ****** **** ****** *********** ******** ** ******* *** ******** ** **** *****.
  14. *** **, **** : **** *** ******** ** ** ******* *** **'* *******.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.